ACS Chem Neurosci. 2019 Apr 17;10(4):2012-2021. doi: 10.1021/acschemneuro.8b00340. Epub 2019 Jan 31.
Recent discoveries have improved our understanding of the physiological and pathological roles of the dopamine transporter (DAT); however, only a few drugs are clinically available for DAT-implicated disorders. Among those drugs, modafinil (MOD) and its ( R)-enantiomer (R-MOD) have been used off-label as therapies for psychostimulant use disorders, but they have shown limited effectiveness in clinical trials. Recent preclinical studies on MOD and R-MOD have led to chemically modified structures aimed toward improving their neurobiological properties that might lead to more effective therapeutics for stimulant use disorders. This study examines three MOD analogues (JJC8-016, JJC8-088, and JJC8-091) with improved DAT affinities compared to their parent compound. These compounds were investigated for their effects on the neurochemistry (brain microdialysis and FSCV) and behavior (ambulatory activity) of male Swiss-Webster mice. Our data indicate that these compounds have dissimilar effects on tonic and phasic dopamine in the nucleus accumbens shell and variability in producing ambulatory activity. These results suggest that small changes in the chemical structure of a DAT inhibitor can cause compounds such as JJC8-088 to produce effects similar to abused psychostimulants like cocaine. In contrast, other compounds like JJC8-091 do not share cocaine-like effects and have a more atypical DAT-inhibitor profile, which may prove to be an advancement in the treatment of psychostimulant use disorders.
最近的发现提高了我们对多巴胺转运体(DAT)的生理和病理作用的理解;然而,只有少数几种药物可用于涉及 DAT 的疾病。在这些药物中,莫达非尼(MOD)及其(R)对映体(R-MOD)已被用作治疗精神兴奋剂使用障碍的标签外药物,但在临床试验中显示出有限的疗效。最近关于 MOD 和 R-MOD 的临床前研究导致了化学修饰的结构,旨在改善其神经生物学特性,这可能为兴奋剂使用障碍提供更有效的治疗方法。本研究检查了三种与母体化合物相比具有改善的 DAT 亲和力的 MOD 类似物(JJC8-016、JJC8-088 和 JJC8-091)。这些化合物被研究了它们对雄性瑞士-韦伯斯特小鼠神经化学(脑微透析和 FSCV)和行为(活动)的影响。我们的数据表明,这些化合物对伏隔核壳中的多巴胺的紧张和脉冲有不同的影响,并且在产生活动方面也存在差异。这些结果表明,DAT 抑制剂化学结构的微小变化会导致像 JJC8-088 这样的化合物产生类似于可卡因等滥用兴奋剂的效果。相比之下,其他化合物如 JJC8-091 则没有可卡因样的效果,具有更典型的 DAT 抑制剂特征,这可能在治疗兴奋剂使用障碍方面是一个进步。